GlassScriptPhysician profile
Murtaza Arif
NPI 1306905187
$4,567.15
in general payments reported to CMS, 2019-2025
27 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,594 · 2020: $711 · 2021: $595 · 2022: $454 · 2023: $387 · 2024: $489 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,152.86 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $961.03 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $328.59 | 2019-2024 | Gattex, Entyvio |
| Boston Scientific Corporation | $274.13 | 2021-2023 | Lux-Dx Insertable Cardiac Monitor |
| Allergan, INC. | $269.06 | 2019-2020 | |
| Braintree Laboratories, INC. | $235.06 | 2019-2025 | Suflave, Sutab |
| Qol Medical, LLC | $191.08 | 2019-2023 | Sucraid |
| Janssen Biotech, INC. | $186.39 | 2019-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $179.50 | 2019-2024 | Linzess |
| Olympus America INC. | $152.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $94.64 | 2019-2021 | |
| Romark Laboratories, Lc | $66.15 | 2019 | |
| Redhill Biopharma INC. | $63.52 | 2020-2024 | Talicia |
| Ardelyx, INC. | $61.42 | 2023 | Ibsrela |
| Lilly USA, LLC | $53.24 | 2023-2024 | Omvoh |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.42 | 2020-2021 | |
| Madrigal Pharmaceuticals | $38.13 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $38.03 | 2019-2020 | |
| Ethicon US, LLC | $34.56 | 2019-2021 | |
| Apollo Endosurgery US INC | $21.59 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $19.60 | 2023 | Exparel |
| Phathom Pharmaceuticals, INC. | $19.06 | 2024 | Voquezna |
| Endo Pharmaceuticals INC. | $19.00 | 2019 | |
| Celgene Corporation | $18.04 | 2021 | |
| W. L. Gore & Associates, INC. | $17.61 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $16.64 | 2019 | |
| Celltrion USA INC. | $14.03 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murtaza Arif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.